Answers are grounded in this paper and cite their sources.
To evaluate systemic complications for timolol, carteolol, levobunolol, and/or betaxalol by using an FDA Federal Adverse Event Reporting System (FAERS).
No takes yet. Share an insight, caveat, or question.
Aftab et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: